AMPH: Amphastar P/S Multiple

Symbol and logo of brand Amphastar Pharmaceuticals Inc (AMPH)

Rising Glucagon sales and the launch of new generics are driving shares higher, as confirmed by the price-to-sales valuation on the GURU.Markets system chart, where the value 1.60 describes the current level. A stable staff of analytical chemists and a loyal R&D center support production. High clinical confidence in the quality of injectable systems solidifies the reputation of Amphastar Pharmaceuticals (AMPH) as a reliable brand.

AMPH Amphastar Corp: Price-to-Revenue Ratio in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for Amphastar (AMPH)

- share price and consensus valuation forecast:
Price Performance Chart amphastar.com|AMPH - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Amphastar|AMPH - Total Company Value
- balance sheet equity data:
Accounting Value per Share Amphastar Pharmaceuticals|AMPH - Company Book Value|Market Capitalization to Net Assets amphastar.com|AMPH - Company Total Assets
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Amphastar Pharmaceuticals|AMPH - Long-Term Debt to Capital|Short-Term Debt to Capital Amphastar Corp|AMPH - Company Debts|Debts to Net Assets Amphastar|AMPH - Company Long-Term Liabilities|Amount of Current Liabilities Amphastar Pharmaceuticals|Quick Ratio amphastar.com
- business earnings and investment ratios data:
AMPH - Company Net Income|Expected Net Income Amphastar Pharmaceuticals|AMPH - Price to Earnings Ratio|Future Price to Earnings Multiple Amphastar Pharmaceuticals Inc|AMPH - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Amphastar|AMPH - Operating profit EBITDA|Earnings per share for the trailing year Amphastar Pharmaceuticals|AMPH - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth amphastar.com|AMPH - Earnings per share growth in current year|Expected earnings per share trend next year Amphastar Pharmaceuticals
- total revenue and sales volume data:
AMPH - Company Revenue|Company Future Sales Volume amphastar.com|AMPH - P/S Multiple|Forward P/S Multiple Amphastar
Fundamental company analysis:AMPH, amphastar.com
Finished products of Amphastar

Utilizing external outsourcing for testing and packaging allows Amphastar Pharmaceuticals (AMPH) to flexibly scale sales while optimizing capital expenditures. The price-to-sales ratio trend reflects the market's valuation of this efficiency by comparing the business value to annual revenue; an increase in this multiple signals inflated investor expectations, which raises the risk of a correction should any deviation from the product implementation plan occur.

Who Amphastar Pharmaceuticals competes with

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple KVUE (Kenvue)|P/S Multiple Verona Pharma PLC VRNA|MENS - Price-to-Revenue Ratio|Ligand Corp (LGND) - Market Cap to Revenue|Amneal Pharmaceuticals (AMRX) - Price-to-Revenue Ratio|Price-to-Sales Ratio PRGO (perrigo.com)|ALVO (Alvotech SA) - P/S Multiple|LQDA: Market Capitalization-to-Revenue Ratio|P/S Multiple GLPG|P/S Multiple ANI Pharmaceuticals Corp (ANIP)|Price-to-Revenue Ratio MannKind Corporation MNKD|Price-to-Revenue Coefficient pacira.com (PCRX)|SPRY: Market Cap to Revenue|Theravance Biopharma Inc - Market Cap to Sales Volume|AQST: P/S Multiple|scPharmaceuticals (SCPH) - P/S Multiple|Price-to-Revenue Ratio Tectonic Therapeutic Inc.|TNXP: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue SXTC (China SXT Pharmaceuticals)|EPRX (eupraxiapharma.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio BioHarvest BHST|EXOZ (Invizyne) - Price-to-Sales Ratio|Oramed Pharma - P/S Multiple|Market Capitalization-to-Revenue Ratio ENTX (Entera Bio Ltd.)|HYFT: P/S Multiple|ABVC BioPharma Inc. (ABVC) - P/S Multiple|Price-to-Revenue Ratio Cumberland Pharma|QNTM: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio FibroGen, Inc. (FGEN)|Market Cap to Revenue telomirpharma.com TELO|P/S Multiple RANI (Rani Therapeutics Holdings, Inc.)|P/S Multiple Synergy CHC Corp. SNYR|Rallybio Corp. - P/S Multiple|Lexaria Bioscience (LEXX) - Market Cap to Revenue|PULM: P/S Multiple|Price to Sales Pheton Holdings (PTHL)|Market Cap to Revenue APM|P/S Multiple Lyra Therapeutics Inc.|Market Cap to Revenue IBO (Impact BioMedical)|Market Cap to Sales Volume TNFA|P/S Multiple YCBD (cbdMD)|Price-to-Revenue Coefficient painreform.com (PRFX)|Auris Medical - P/S Multiple|Lipella Pharmaceuticals Inc (LIPO) - Market Cap to Revenue|OPTN: P/S Multiple|Pieris Pharma (PIRS) - P/S Multiple|Price-to-Revenue Ratio Procaps Group S.A.|Price-to-Revenue Ratio PTPI|Price-to-Revenue Ratio Qilian International Holding (QLI)|Price-to-Revenue Coefficient Acelyrin Inc.|P/S Multiple TFFP (TFF Pharma)